|Dr. Christopher R. Anzalone||CEO, Pres & Director||2.22M||3.72M||1969|
|Mr. Kenneth A. Myszkowski||Chief Financial Officer||685.85k||759.46k||1966|
|Mr. Patrick O'Brien||Gen. Counsel & Corp. Sec.||683.54k||N/A||1964|
|Dr. Bruce D. Given||Advisor||1.35M||3.53M||1954|
|Dr. Mark M. Davis||Founder and Founder & Director of Insert Therapeutics Inc & Calando||N/A||N/A||N/A|
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD for treating liver diseases; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals, Inc.’s ISS governance QualityScore as of 5 December 2019 is 7. The pillar scores are Audit: 2; Board: 10; Shareholder rights: 2; Compensation: 4.